<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02963077</url>
  </required_header>
  <id_info>
    <org_study_id>A4250-001</org_study_id>
    <secondary_id>2013-001175-21</secondary_id>
    <nct_id>NCT02963077</nct_id>
  </id_info>
  <brief_title>A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384</brief_title>
  <official_title>A Phase I, Double-Blind Single and Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of A4250 as Monotherapy, and in Combination With Colonic Release Cholestyramine (A3384) or Commercially Available Cholestyramine (Questran™) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albireo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albireo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of the study are to evaluate the safety, tolerability and
      pharmacokinetics of A4250 after single or multiple oral doses in healthy subjects. In
      addition, will evaluate A4250 in combination with cholestyramine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean (± SD) Plasma Pharmacokinetic Concentrations of A4250 Following A Single Oral 10 mg A4250 Dose - Tmax</measure>
    <time_frame>Pharmacokinetic blood samples were taken pre-dose, and post-dose at: 0.5 hour, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean (± SD) Plasma Pharmacokinetic Concentrations of A4250 Following a Single Oral 10 mg A4250 Dose - Cmax</measure>
    <time_frame>Pharmacokinetic blood samples were taken pre-dose, and post-dose at: 0.5 hour, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean (± SD) Plasma Pharmacokinetic Concentrations of A4250 Following a Single Oral 10 mg A4250 Dose - AUC 0-t</measure>
    <time_frame>Pharmacokinetic blood samples were taken pre-dose, and post-dose at: 0.5 hour, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean (SD) Change in FGF19 from Day 1 Pre-Dose to 4 h Post-Dose</measure>
    <time_frame>Pharmacodynamic blood samples were taken pre-dose and at 4 hours and 24 hours post-dosing, and at follow-up (5-7 days after final dose).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean (SD) Change in FGF19 from Day 1 Pre-Dose to 24 h Post-Dose</measure>
    <time_frame>Pharmacodynamic blood samples were taken pre-dose and at 4 hours and 24 hours post-dosing, and at follow-up (5-7 days after final dose).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean (SD) Change in C4 from Day 1 Pre-Dose to 4 h Post-Dose</measure>
    <time_frame>Pharmacodynamic blood samples were taken pre-dose and at 4 hours and 24 hours post-dosing, and at follow-up (5-7 days after final dose).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean (SD) Change in C4 from Day 1 Pre-Dose to 24 h Post-Dose</measure>
    <time_frame>Pharmacodynamic blood samples were taken pre-dose and at 4 hours and 24 hours post-dosing, and at follow-up (5-7 days after final dose).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean (SD) Changes in Total Bile Acids for A4250 4 h compared to pre-dose</measure>
    <time_frame>Samples were taken pre-dose and post-dose at 4 hours and 24 hours.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean (SD) Changes in Total Bile Acids for A4250 24 h compared to pre-dose</measure>
    <time_frame>Samples were taken pre-dose, and post-dose at 4 hours and 24 hours.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric (geometric CV%) Mean for AUC(0-12) on Day 7 for plasma FGF19</measure>
    <time_frame>AUC(0-12) on Day 7 (only for Part II)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric (geometric CV%) Mean for AUC(0-12) on Day 7 for plasma C4</measure>
    <time_frame>AUC(0-12) on Day 7 (only Part II)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric (geometric CV%) Mean for AUC(0-12) on Day 7 for plasma Total Bile Acids</measure>
    <time_frame>AUC(0-12) on Day 7 (only Part II)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean (SD) Changes in Faecel Total Bile Acids from Day 1 Pre-Dose on Day 7 at 24 h Post-dose</measure>
    <time_frame>Change from Day 1 Pre-dose to Day 7 at 24 hours Post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean (SD) Change in Faecal Total Bile Acids Excreted (ng) from Day 1 Pre-Dose on Day 7 Post-Dose</measure>
    <time_frame>Change from Day 1 Pre-dose to Day 7 at 24 hours Post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>24</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Orphan Cholestatic Liver Diseases</condition>
  <condition>Primary Biliary Cirrhosis</condition>
  <condition>Progressive Familial Intrahepatic Cholestasis</condition>
  <condition>Alagille Syndrome</condition>
  <arm_group>
    <arm_group_label>Cohort 1 SAD - 0.1 mg A4250</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose: 0.1 mg of A4250. Sentinel dosing was used (2 sub-cohorts dosed a minimum of 24 h apart).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 SAD - 0.3 mg A4250</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose: 0.3 mg of A4250.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 SAD - 1 mg A4250</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose: 1 mg A4250.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 SAD - 3 mg A4250</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose: 3 mg A4250.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 SAD - 10 mg A4250</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose: 10 mg A4250.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 SAD placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose: 0.1 mg of A4250 matching placebo. Sentinel dosing was used (2 sub-cohorts dosed a minimum of 24 h apart).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 SAD placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose: 0.3 mg A4250 matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 SAD placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose: 1 mg A4250 matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 SAD placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose: 3 mg A4250 matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 SAD placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose: 10 mg A4250 matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 MAD - 1 mg A4250 qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose: 1 mg A4250 qd for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 MAD placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose: 1 mg A4250 matching placebo qd for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 MAD - 3 mg A4250</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose: 3 mg A4250 qd for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 MAD placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose: 3 mg A4250 matching placebo qd for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 MAD - 1.5 mg A4250 b.i.d for 7 days.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose: 1.5 mg A4250 b.i.d. for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 MAD placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose: 1.5 A4250 matching placebo b.i.d for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 MAD - 3 mg A4250 qd + 1 mg Questran b.i.d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose: 3 mg A4250 qd + 1 mg Questran b.i.d for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 MAD A4250 placebo + 1 mg Questran b.i.d</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose: 3 mg A4250 matching placebo + 1 mg Questran b.i.d for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 MAD - 3 mg A4250 qd + 1 g CRC b.i.d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose: 3 mg A4250 qd + 1 g CRC b.i.d for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 MAD A4250 placebo + CRC placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose: 3 mg A4250 matching placebo qd + 1 g CRC placebo b.i.d for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 MAD - 1 g CRC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose: 1 g CRC b.i.d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 MAD CRC placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose: 1 g CRC matching placebo b.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7 MAD - 3 mg A4250 qd + 1 g CRC b.i.d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose: 3 mg A4250 qd + 1 g CRC b.i.d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7 MAD A4250 placebo + CRC placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose: 3 mg A4250 matching placebo qd + 1 g CRC matching placebo b.i.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A4250</intervention_name>
    <arm_group_label>Cohort 1 SAD - 0.1 mg A4250</arm_group_label>
    <arm_group_label>Cohort 2 SAD - 0.3 mg A4250</arm_group_label>
    <arm_group_label>Cohort 3 SAD - 1 mg A4250</arm_group_label>
    <arm_group_label>Cohort 4 SAD - 3 mg A4250</arm_group_label>
    <arm_group_label>Cohort 5 SAD - 10 mg A4250</arm_group_label>
    <arm_group_label>Cohort 1 MAD - 1 mg A4250 qd</arm_group_label>
    <arm_group_label>Cohort 2 MAD - 3 mg A4250</arm_group_label>
    <arm_group_label>Cohort 3 MAD - 1.5 mg A4250 b.i.d for 7 days.</arm_group_label>
    <arm_group_label>Cohort 4 MAD - 3 mg A4250 qd + 1 mg Questran b.i.d</arm_group_label>
    <arm_group_label>Cohort 5 MAD - 3 mg A4250 qd + 1 g CRC b.i.d</arm_group_label>
    <arm_group_label>Cohort 7 MAD - 3 mg A4250 qd + 1 g CRC b.i.d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CRC (A3384)</intervention_name>
    <arm_group_label>Cohort 5 MAD - 3 mg A4250 qd + 1 g CRC b.i.d</arm_group_label>
    <arm_group_label>Cohort 6 MAD - 1 g CRC</arm_group_label>
    <arm_group_label>Cohort 7 MAD - 3 mg A4250 qd + 1 g CRC b.i.d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Questran</intervention_name>
    <arm_group_label>Cohort 4 MAD - 3 mg A4250 qd + 1 mg Questran b.i.d</arm_group_label>
    <arm_group_label>Cohort 4 MAD A4250 placebo + 1 mg Questran b.i.d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort 1 SAD placebo</arm_group_label>
    <arm_group_label>Cohort 2 SAD placebo</arm_group_label>
    <arm_group_label>Cohort 3 SAD placebo</arm_group_label>
    <arm_group_label>Cohort 4 SAD placebo</arm_group_label>
    <arm_group_label>Cohort 5 SAD placebo</arm_group_label>
    <arm_group_label>Cohort 1 MAD placebo</arm_group_label>
    <arm_group_label>Cohort 2 MAD placebo</arm_group_label>
    <arm_group_label>Cohort 3 MAD placebo</arm_group_label>
    <arm_group_label>Cohort 4 MAD A4250 placebo + 1 mg Questran b.i.d</arm_group_label>
    <arm_group_label>Cohort 5 MAD A4250 placebo + CRC placebo</arm_group_label>
    <arm_group_label>Cohort 6 MAD CRC placebo</arm_group_label>
    <arm_group_label>Cohort 7 MAD A4250 placebo + CRC placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males or non-pregnant, non-lactating healthy females

          2. BMI of 18 to 32 kg/m2 or, if outside the range, considered not clinically significant
             by the investigator

          3. Willing and able to communicate and participate in the whole study

          4. Provided written informed consent

          5. Agreed to use an adequate method of contraception

        Exclusion Criteria:

          1. Had participated in a clinical research study within the previous 3 months

          2. Were study site employees, or immediate family members of a study site or sponsor
             employee

          3. Had previously been enrolled in this study

          4. History of any drug or alcohol abuse in the past 2 years

          5. Regular alcohol consumption, in males &gt;21 units per week and females &gt;14 units per
             week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)

          6. Current smokers and those who had smoked within the last 12 months. A breath carbon
             monoxide (CO) reading of greater than 10 ppm at screening

          7. Females of childbearing potential who were pregnant or lactating (female subjects must
             have had a negative urine pregnancy test at admission)

          8. Did not have suitable veins for multiple venepunctures/cannulation as assessed by the
             investigator at screening

          9. Clinically significant abnormal biochemistry, haematology or urinalysis as judged by
             the investigator

         10. Positive drugs of abuse test result

         11. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or
             human immunodeficiency virus (HIV) results

         12. History of cardiovascular, renal, hepatic, chronic respiratory or GI disease as judged
             by the investigator

         13. Serious adverse reaction or serious hypersensitivity to any drug or the formulation
             excipients eg lactose or contraindications to cholestyramine/Questran

         14. Presence or history of clinically significant allergy requiring treatment as per the
             judgement of the investigator Hayfever was allowed unless it was active

         15. Donation or loss of greater than 400 mL of blood within the previous 3 months

         16. Were taking, or had taken, any prescribed or over-the-counter drug (other than up to 4
             g per day paracetamol, hormone replacement therapy [HRT] and hormonal contraception)
             or herbal remedies in the 14 days before IMP administration unless they were not
             considered to have interfered with the objectives of the study, as agreed by the PI
             and sponsor's medical monitor on a case by case basis

         17. Failed to satisfy the investigator of fitness to participate for any other reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mats Ekelund, MD</last_name>
    <role>Study Director</role>
    <affiliation>Albireo</affiliation>
  </overall_official>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2016</study_first_posted>
  <last_update_submitted>November 15, 2016</last_update_submitted>
  <last_update_submitted_qc>November 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
    <mesh_term>Cholestasis, Intrahepatic</mesh_term>
    <mesh_term>Alagille Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestyramine Resin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

